Biomarin Pharmaceutical (BMRN) Research & Development (2009 - 2026)
Biomarin Pharmaceutical's Research & Development was $206.95 million in Q2 2026, up 28.3% from $161.31 million a year earlier and up 15.7% from the prior quarter.
Biomarin Pharmaceutical (BMRN) Research & Development (2009 - 2026) Analysis & Trends
On a trailing twelve-month basis, Biomarin Pharmaceutical's Research & Development was $987.64 million through Jun 30, 2026, up 45.6% year-over-year; for FY2025, it was $921.93 million, up 23.4% from FY2024.
- Research & Development has now increased for five consecutive years, with a five-year compound annual growth rate of 8.0% (FY2020 to FY2025).
- In earlier years, Research & Development was $747.18 million in FY2024 (+0.1%), $746.77 million in FY2023 (+15.0%), $649.61 million in FY2022 (+3.3%) and $628.79 million in FY2021 (+0.1%).
- Quarterly Research & Development has moved between $157.83 million (Q3 2022) and $409.48 million (Q3 2025) over five years.
- Compared with a year earlier, Research & Development has increased for four straight quarters, with growth averaging 14.9% over the last eight quarters.
- The best year-over-year quarter for Research & Development over five years was Q3 2025 (growth of 121.5%); the worst was Q1 2025 (a decline of 22.6%).
- Per Business Quant data, BMRN's Research & Development in the three quarters before Q2 2026 was $178.8 million (Q1 2026), $192.41 million (Q4 2025) and $409.48 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Biomarin Pharmaceutical | 11.51 Bn | 5.37 Bn | 786.91 Mn | 206.95 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 206.95 Mn |
| Mar 31, 2026 | 178.80 Mn |
| Dec 31, 2025 | 192.41 Mn |
| Sep 30, 2025 | 409.48 Mn |
| Jun 30, 2025 | 161.31 Mn |
| Mar 31, 2025 | 158.73 Mn |
| Dec 31, 2024 | 173.51 Mn |
| Sep 30, 2024 | 184.90 Mn |
| Jun 30, 2024 | 183.79 Mn |
| Mar 31, 2024 | 204.99 Mn |
| Dec 31, 2023 | 206.25 Mn |
| Sep 30, 2023 | 191.31 Mn |
| Jun 30, 2023 | 177.36 Mn |
| Mar 31, 2023 | 171.85 Mn |
| Dec 31, 2022 | 172.75 Mn |
| Sep 30, 2022 | 157.83 Mn |
| Jun 30, 2022 | 158.19 Mn |
| Mar 31, 2022 | 160.84 Mn |
| Dec 31, 2021 | 161.09 Mn |
| Sep 30, 2021 | 157.87 Mn |
Biomarin Pharmaceutical Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=BMRN&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "BMRN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=BMRN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();